Skip to content

Depression: all studies

Page 87 of 1,034: studies 861 to 870 of 10,336, newest first. Back to the depression overview

Research

Racial-Ethnic Disparities in Ketamine and Esketamine Therapy for Major Depressive Disorder.

Psychiatric Services June 25, 2025 Michael Liu, Rachel Branning, Austin Lee et al. 2 citations

This study sought to investigate racial-ethnic disparities in the utilization of intravenous ketamine and intranasal esketamine therapy for major depressive disorder. The TriNetX platform was used to identify 861,179 patients diagnosed as having moderate-to-severe recurrent major depressive disorder between January 2019 and October 2024. Patients were divided into non-Hispanic White,...

DOI: 10.1176/appi.ps.20240559 (opens in new tab) Full text (opens in new tab) Esketamine Racial-ethnic disparities Unequal access Healthcare disparities +10

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

Drugs Aging June 24, 2025 Lou Vinarcsik, Charles Smoller, George Grossberg 1 citation

The use of drugs with psychedelic and dissociative effects for the treatment of psychiatric illnesses has become increasingly popular in recent years. However, few trials have been conducted to determine the efficacy of these agents in the specific setting of treatment-resistant major depressive disorder (MDD) in older adults. In this paper, we review notable aspects of treatment-resistant MDD...

DOI: 10.1007/s40266-025-01221-5 (opens in new tab) Innovative approach New avenue Agents Treatment +11

MeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses.

iScience June 20, 2025 Michelle K Piazza, Abigael R Weit, Ege T Kavalali et al. 2 citations

Ketamine induces antidepressant action via upregulation of hippocampal brain-derived neurotrophic factor (BDNF) expression and TrkB receptor signaling. Rett syndrome (RTT), a neurodevelopmental disorder caused by mutations in Methyl-CpG-binding protein 2 (MECP2), is associated with decreased BDNF expression. Although treatment with ketamine or LM22A-4, a TrkB receptor agonist, improves...

DOI: 10.1016/j.isci.2025.112485 (opens in new tab) Full text (opens in new tab) Ketamine Biological sciences Molecular neuroscience Natural sciences +3

Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times.

Journal of Psychopharmacology June 18, 2025 Maria Bălăeţ, William Trender, Annalaura Lerede et al. 2 citations

Mental health implications of COVID-19 drug use patterns are still unclear. We used data-driven clustering in a large citizen science cohort recruited agnostically to an interest in drug-use to categorise people according to common patterns of drug use and analysed their mental health symptoms (GAD-7 and PHQ-9 items), from recruitment prior to COVID-19 restrictions in 2020 (N = 242,260) to...

DOI: 10.1177/02698811251346729 (opens in new tab) Full text (opens in new tab) Well-being Reduced anxiety Reduced depression Improved mental health +5

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression

The British Journal of Psychiatry June 18, 2025 Kyle T. Greenway, Nicolas Garel, Lê-Anh Dinh-Williams et al. 8 citations

Background Ketamine exerts potent but transient antidepressant effects in treatment-resistant depression (TRD). Combinations of ketamine and psychotherapy have attracted interest, but no trial has investigated a psychedelic model of ketamine–psychotherapy for TRD to our knowledge. Aims This secondary analysis of a randomised clinical trial (RCT) explores the therapeutic effects and experiential...

Comparison of cognitive behavioral therapy and third-wave-mindfulness-based therapies for patients suffering from depression measured using the Beck-Depression-Inventory (BDI): A systematic literature review and network-meta-analysis.

Journal of Affective Disorders June 15, 2025 Alexander Buschner, Christian Makiol, Jue Huang et al. 5 citations

Mindfulness-based therapies (MBT) are proposed as a "third wave" of cognitive-behavioral therapy (CBT). This network meta-analysis investigated this hypothesis by comparing the effectiveness of MBT and CBT for treating depression, measured by the Beck Depression Inventory-II (BDI-II). An indirect comparison was made. Relevant databases were searched for studies comparing either CBT or MBT with...

DOI: 10.1016/j.jad.2025.02.104 (opens in new tab) Full text (opens in new tab) Depression Cognitive behavioral therapy Meta-analysis Mindfulness-based-cognitive-therapy +2

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology June 15, 2025 Daniël Hoyer 9 citations

Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N , N ‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g. ibogaine, ketamine and esketamine; and other atypicals e.g. dextromorphan/bupropion, esmethadone....

Network localization of functional brain changes associated with ketamine's therapeutic effects in depression.

Biological Psychiatry June 13, 2025 Shaoqiang Han, Ya Tian, Huiting Yang et al. 1 citation

Although numerous studies have attempted to identify the functional pathways underlying the rapid antidepressant effects of ketamine, their findings remain inconsistent, limiting our understanding of the neural mechanisms involved. This study aims to delineate a specific brain circuit by integrating diverse functional findings related to ketamine's efficacy in depression. We conducted a...

DOI: 10.1016/j.biopsych.2025.06.006 (opens in new tab) Full text (opens in new tab) Ketamine: ketamine Therapeutic effects Unique power Depression: depression +8

Mechanics of Mindfulness: Investigating Metacognitive Beliefs as a Pathway of Effect on Anxiety and Depression.

European Journal of Investigation in Health, Psychology and Education June 12, 2025 Corey Jackson, Christian M Jones 2 citations

This study aimed to address the dearth of literature on mechanisms of effect of mindfulness-based interventions by investigating metacognitive beliefs as a potential mechanism of symptomology-reduction effects. The Cognitive Attentional Syndrome (CAS) component of the Self-Regulatory Executive Function (S-REF) model was augmented to include subtypes of mind wandering and rumination. One hundred...

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

DOI: 10.1016/j.jad.2025.119632 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonists Posttraumatic Stress Treatment resistant depression +6